{"count": 6, "results": [{"_id": "36077749", "pmid": 36077749, "pmcid": "PMC9454423", "title": "Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma", "journal": "Cancers (Basel)", "authors": ["Arnason TG", "MacDonald-Dickinson V", "Gaunt MC", "Davies GF", "Lobanova L", "Trost B", "Gillespie ZE", "Waldner M", "Baldwin P", "Borrowman D", "Marwood H", "Vizeacoumar FS", "Vizeacoumar FJ", "Eskiw CH", "Kusalik A", "Harkness TAA"], "date": "2022-08-30T00:00:00Z", "doi": "10.3390/cancers14174215", "meta_date_publication": "2022 Aug 30", "meta_volume": "14", "meta_issue": "17", "meta_pages": "", "score": 50263.49, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ reduced @<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@MDR@@@ protein markers in all @SPECIES_9615 @@@canines@@@ in the study. ", "citations": {"NLM": "Arnason TG, MacDonald-Dickinson V, Gaunt MC, Davies GF, Lobanova L, Trost B, Gillespie ZE, Waldner M, Baldwin P, Borrowman D, Marwood H, Vizeacoumar FS, Vizeacoumar FJ, Eskiw CH, Kusalik A, Harkness TAA. Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma Cancers (Basel). 2022 Aug 30;14(17):. PMID: 36077749", "BibTeX": "@article{36077749, title={Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma}, author={Arnason TG and MacDonald-Dickinson V and Gaunt MC and Davies GF and Lobanova L and Trost B and Gillespie ZE and Waldner M and Baldwin P and Borrowman D and Marwood H and Vizeacoumar FS and Vizeacoumar FJ and Eskiw CH and Kusalik A and Harkness TAA}, journal={Cancers (Basel)}, volume={14}, number={17}}"}}, {"_id": "37737447", "pmid": 37737447, "pmcid": "PMC10747420", "title": "New insights on the potential anti-epileptic effect of metformin: Mechanistic pathway", "journal": "J Cell Mol Med", "authors": ["Alnaaim SA", "Al-Kuraishy HM", "Al-Gareeb AI", "Ali NH", "Alexiou A", "Papadakis M", "Saad HM", "Batiha GE"], "date": "2023-09-22T00:00:00Z", "doi": "10.1111/jcmm.17965", "meta_date_publication": "2023 Sep 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50259.387, "text_hl": "In conclusion, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ might be an adjuvant with AEAs in the management of @<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@refractory epilepsy@@@. ", "citations": {"NLM": "Alnaaim SA, Al-Kuraishy HM, Al-Gareeb AI, Ali NH, Alexiou A, Papadakis M, Saad HM, Batiha GE. New insights on the potential anti-epileptic effect of metformin: Mechanistic pathway J Cell Mol Med. 2023 Sep 22;():. PMID: 37737447", "BibTeX": "@article{37737447, title={New insights on the potential anti-epileptic effect of metformin: Mechanistic pathway}, author={Alnaaim SA and Al-Kuraishy HM and Al-Gareeb AI and Ali NH and Alexiou A and Papadakis M and Saad HM and Batiha GE}, journal={J Cell Mol Med}}"}}, {"_id": "37067582", "pmid": 37067582, "pmcid": "PMC10497685", "title": "Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine", "journal": "Naunyn Schmiedebergs Arch Pharmacol", "authors": ["Harby SA", "Khalil NA", "El-Sayed NS", "Thabet EH", "Saleh SR", "Fathelbab MH"], "date": "2023-04-17T00:00:00Z", "doi": "10.1007/s00210-023-02485-7", "meta_date_publication": "2023 Apr 17", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50249.383, "text_hl": "@GENE_ABCG2 @GENE_26357 @@@BCRP@@@ has a significant role in @DISEASE_Epilepsy @DISEASE_MESH:D004827 @@@epilepsy@@@ resistance and its inhibition with @CHEMICAL_3_(6_isobutyl_9_methoxy_1_4_dioxo_1_2_3_4_6_7_12_12a_octahydropyrazino(1'_2'_1_6)pyrido(3_4_b)indol_3_yl)propionic_acid_tert_butyl_ester @CHEMICAL_MESH:C541506 @@@ko143@@@ or @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ adds value to @<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@DRE@@@ management.", "citations": {"NLM": "Harby SA, Khalil NA, El-Sayed NS, Thabet EH, Saleh SR, Fathelbab MH. Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine Naunyn Schmiedebergs Arch Pharmacol. 2023 Apr 17;():. PMID: 37067582", "BibTeX": "@article{37067582, title={Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine}, author={Harby SA and Khalil NA and El-Sayed NS and Thabet EH and Saleh SR and Fathelbab MH}, journal={Naunyn Schmiedebergs Arch Pharmacol}}"}}, {"_id": "40678416", "pmid": 40678416, "title": "The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells.", "journal": "Turk J Biol", "authors": ["Cingir Köker Ş", "Noyan S", "Yalçin B", "Doğan Turaçli İ"], "date": "2025-03-17T00:00:00Z", "doi": "10.55730/1300-0152.2749", "meta_date_publication": "2025", "meta_volume": "49", "meta_issue": "3", "meta_pages": "336-346", "score": 50242.695, "text_hl": "@<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@Drug resistance@@@ can develop with any therapeutic agent, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ is no exception. ", "citations": {"NLM": "Cingir Köker Ş, Noyan S, Yalçin B, Doğan Turaçli İ. The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells. Turk J Biol. 2025;49(3):336-346. PMID: 40678416", "BibTeX": "@article{40678416, title={The effects of hsa-mir-26a-5p on cell proliferation, migration, and PI3K inhibitor sensitivity in metformin-resistant triple negative breast cancer cells.}, author={Cingir Köker Ş and Noyan S and Yalçin B and Doğan Turaçli İ}, journal={Turk J Biol}, volume={49}, number={3}, pages={336-346}}"}}, {"_id": "32183127", "pmid": 32183127, "pmcid": "PMC7141290", "title": "Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease", "journal": "J Clin Med", "authors": ["Bezabhe WM", "Kitsos A", "Saunder T", "Peterson GM", "Bereznicki LR", "Wimmer BC", "Jose M", "Radford J"], "date": "2020-03-13T00:00:00Z", "doi": "10.3390/jcm9030783", "meta_date_publication": "2020 Mar 13", "meta_volume": "9", "meta_issue": "3", "meta_pages": "", "score": 50233.953, "text_hl": "The study examined the proportion of @SPECIES_9606 @@@patients@@@ with @DISEASE_Renal_Insufficiency_Chronic @DISEASE_MESH:D051436 @@@CKD@@@ who met a set of 16 published indicators in two categories: (1) potentially appropriate prescribing of antihypertensives, @GENE_REN @GENE_5972 @@@renin@@@-angiotensin system (RAS) inhibitors, phosphate binders, and statins; and (2) potentially inappropriate prescribing of @<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@nephrotoxic medications@@@, such as non-steroidal anti-inflammatory drugs (NSAIDs), at least two RAS inhibitors, triple therapy (an NSAID, a RAS inhibitor and a diuretic), high-dose @CHEMICAL_Digoxin @CHEMICAL_MESH:D004077 @@@digoxin@@@, and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Bezabhe WM, Kitsos A, Saunder T, Peterson GM, Bereznicki LR, Wimmer BC, Jose M, Radford J. Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease J Clin Med. 2020 Mar 13;9(3):. PMID: 32183127", "BibTeX": "@article{32183127, title={Medication Prescribing Quality in Australian Primary Care Patients with Chronic Kidney Disease}, author={Bezabhe WM and Kitsos A and Saunder T and Peterson GM and Bereznicki LR and Wimmer BC and Jose M and Radford J}, journal={J Clin Med}, volume={9}, number={3}}"}}, {"_id": "38256477", "pmid": 38256477, "pmcid": "PMC10816903", "title": "Drug-Related Problems and Sick Day Management Considerations for Medications that Contribute to the Risk of Acute Kidney Injury", "journal": "J Clin Med", "authors": ["Truong M", "Tesfaye W", "Sud K", "Van C", "Seth S", "Croker N", "Castelino RL"], "date": "2024-01-07T00:00:00Z", "doi": "10.3390/jcm13020343", "meta_date_publication": "2024 Jan 7", "meta_volume": "13", "meta_issue": "2", "meta_pages": "", "score": 50231.85, "text_hl": "It is recommended that potentially @<m>DISEASE_Drug_Resistant_Epilepsy</m> @DISEASE_MESH:D000069279 @@@nephrotoxic medications@@@ are withheld during acute illness, including @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylureas@@@, angiotensin converting enzyme inhibitors, diuretics, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, angiotensin receptor blockers, non-steroidal anti-inflammatories and sodium glucose co-transporter 2 inhibitors (SADMANS). ", "citations": {"NLM": "Truong M, Tesfaye W, Sud K, Van C, Seth S, Croker N, Castelino RL. Drug-Related Problems and Sick Day Management Considerations for Medications that Contribute to the Risk of Acute Kidney Injury J Clin Med. 2024 Jan 7;13(2):. PMID: 38256477", "BibTeX": "@article{38256477, title={Drug-Related Problems and Sick Day Management Considerations for Medications that Contribute to the Risk of Acute Kidney Injury}, author={Truong M and Tesfaye W and Sud K and Van C and Seth S and Croker N and Castelino RL}, journal={J Clin Med}, volume={13}, number={2}}"}}]}